{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:54:50Z","timestamp":1781787290474,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007594","name":"Univerzita Komensk\u00e9ho v Bratislave","doi-asserted-by":"publisher","award":["UK\/1066\/2025"],"award-info":[{"award-number":["UK\/1066\/2025"]}],"id":[{"id":"10.13039\/100007594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"VEGA","doi-asserted-by":"crossref","award":["1\/0065\/25"],"award-info":[{"award-number":["1\/0065\/25"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer ranks as the most diagnosed oncological disease in Slovak men and the third most common cause of their cancer related mortality. G-protein coupled estrogen receptor 1 (GPER1) is estrogen receptor mediating fast non-genomic estrogen signaling and shown potential as therapeutic target for later stages of the disease and in chemoprevention. However, little is currently known about the impact of genetic variability in the GPER1 gene on the prostate cancer risk and disease characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Genomic DNA samples isolated from peripheral blood of 701 prostate cancer patients and 659 healthy men were used for the single nucleotide polymorphism (SNP) analysis. The presence of GPER1 SNPs (rs3808350, rs3808351, rs11544331) was determined by ARMS-PCR. GPER1 expression was quantified by semi-quantitative RT-PCR using mRNA isolated from prostate cancer tissues and using benign prostate hyperplasia tissues as a control. The GPER1 SNP rs3808350 was associated with a higher risk of developing prostate cancer, especially in patients with a Gleason score\u2009\u2265\u20097 and with nodal and distant metastases. No association was found between the rs3808351 and rs11544331 and prostate cancer. No significant changes in GPER1 expression were found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The GPER1 rs3808350 was associated with a higher risk of prostate cancer as well as with its characteristics and appears to influence prostate cancer susceptibility and aggressiveness. In the future, these findings could help in personalized treatment and prognosis determination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-026-12131-z","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:16:18Z","timestamp":1781784978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between the G-protein-coupled estrogen receptor 1 and prostate cancer in the Slovak population"],"prefix":"10.1007","volume":"53","author":[{"given":"Martina","family":"Me\u010diakov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1n","family":"Kliment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3bert","family":"Du\u0161enka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Evin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kno\u0161ko Bro\u017eov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kme\u0165ov\u00e1 Sivo\u0148ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161an","family":"Dobrota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Jure\u010dekov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"10437","key":"12131_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J et al (2024) The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403(10437):1683\u20131722. https:\/\/doi.org\/10.1016\/S0140-6736(24)00651-2","journal-title":"Lancet"},{"key":"12131_CR2","unstructured":"IARC (2026) Global Cancer Observatory: Cancer Today. Data visualization tool for cancer incidence and mortality. https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/pie?mode=cancer&group_populations=1&sexes=1&populations=703. Accessed 8 April 2026"},{"issue":"2","key":"12131_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, Mucci L, Morgan TM, Carlsson SV (2023) 2022 Update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol 84(2):191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021","journal-title":"Eur Urol"},{"issue":"1","key":"12131_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE et al (2021) Prostate cancer. Nat Rev Dis Primers 7(1):9. https:\/\/doi.org\/10.1038\/s41572-020-00243-0","journal-title":"Nat Rev Dis Primers"},{"key":"12131_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","volume":"62","author":"D Westaby","year":"2022","unstructured":"Westaby D, de La Fenor MLD, Paschalis A, Jimenez-Vacas JM, Welti J, de Bono J, Sharp A (2022) A new old target: androgen receptor signaling and advanced prostate cancer. Annu Rev Pharmacol Toxicol 62:131\u2013153. https:\/\/doi.org\/10.1146\/annurev-pharmtox-052220-015912","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"12131_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3322\/canjclin.22.4.232","volume":"22","author":"C Huggins","year":"1972","unstructured":"Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22(4):232\u2013240. https:\/\/doi.org\/10.3322\/canjclin.22.4.232","journal-title":"CA Cancer J Clin"},{"key":"12131_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-3-319-71553-7_5","volume-title":"Recent Trends in Cancer Biology: Spotlight on Signaling Cascades and MicroRNAs: Cell Signaling Pathways and MicroRNAs in Cancer Biology","author":"M Figueira","year":"2018","unstructured":"Figueira M, Cardoso H, Socorro S (2018) The role of GPER signaling in carcinogenesis: a focus on prostate cancer. Recent Trends in Cancer Biology: Spotlight on Signaling Cascades and MicroRNAs: Cell Signaling Pathways and MicroRNAs in Cancer Biology. Springer, Cham, pp 59\u2013117. https:\/\/doi.org\/10.1007\/978-3-319-71553-7_5"},{"issue":"10","key":"12131_CR8","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/js.2019-00178","volume":"3","author":"S Chadid","year":"2019","unstructured":"Chadid S, Barber JR, Rohrmann S, Nelson WG, Yager JD, Kanarek NF, Bradwin G, Dobs AS, McGlynn KA, Platz EA (2019) Age-specific serum total and free estradiol concentrations in healthy men in US nationally representative samples. J Endocr Soc 3(10):1825\u20131836. https:\/\/doi.org\/10.1210\/js.2019-00178","journal-title":"J Endocr Soc"},{"issue":"5","key":"12131_CR9","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1530\/EJE-18-1000","volume":"181","author":"N Russell","year":"2019","unstructured":"Russell N, Grossmann M (2019) Mechanisms in endocrinology: estradiol as a male hormone. Eur J Endocrinol 181(5):R23\u2013R43. https:\/\/doi.org\/10.1530\/EJE-18-1000","journal-title":"Eur J Endocrinol"},{"key":"12131_CR10","doi-asserted-by":"publisher","first-page":"811578","DOI":"10.3389\/fendo.2021.811578","volume":"12","author":"A Ram\u00edrez-de-Arellano","year":"2022","unstructured":"Ram\u00edrez-de-Arellano A, Pereira-Su\u00e1rez AL, Rico-Fuentes C, L\u00f3pez-Pulido EI, Villegas-Pineda JC, Sierra-Diaz E (2022) Distribution and effects of estrogen receptors in prostate cancer: associated molecular mechanisms. Front Endocrinol 12:811578. https:\/\/doi.org\/10.3389\/fendo.2021.811578","journal-title":"Front Endocrinol"},{"issue":"7","key":"12131_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41574-023-00822-7","volume":"19","author":"ER Prossnitz","year":"2023","unstructured":"Prossnitz ER, Barton M (2023) The G protein-coupled oestrogen receptor GPER in health and disease: an update. Nat Rev Endocrinol 19(7):407\u2013424. https:\/\/doi.org\/10.1038\/s41574-023-00822-7","journal-title":"Nat Rev Endocrinol"},{"key":"12131_CR12","doi-asserted-by":"publisher","first-page":"108822","DOI":"10.1016\/j.pharmthera.2025.108822","volume":"269","author":"A Bushi","year":"2025","unstructured":"Bushi A, Ma Y, Adu-Amankwaah J, Wang R, Cui F, Xiao R, Zhao J, Yuan J, Tan R (2025) G protein-coupled estrogen receptor biased signaling in health and disease. Pharmacol Ther 269:108822. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108822","journal-title":"Pharmacol Ther"},{"issue":"4","key":"12131_CR13","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.3390\/ijms24044043","volume":"24","author":"A Wnuk","year":"2023","unstructured":"Wnuk A, Przepi\u00f3rska K, Pietrzak BA, Kajta M (2023) Emerging evidence on membrane estrogen receptors as novel therapeutic targets for central nervous system pathologies. Int J Mol Sci 24(4):4043. https:\/\/doi.org\/10.3390\/ijms24044043","journal-title":"Int J Mol Sci"},{"issue":"5","key":"12131_CR14","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s10571-022-01301-9","volume":"43","author":"S Upadhayay","year":"2023","unstructured":"Upadhayay S, Gupta R, Singh S, Mundkar M, Singh G, Kumar P (2023) Involvement of the G-protein-coupled estrogen receptor-1 (GPER) signaling pathway in neurodegenerative disorders: a review. Cell Mol Neurobiol 43(5):1833\u20131847. https:\/\/doi.org\/10.1007\/s10571-022-01301-9","journal-title":"Cell Mol Neurobiol"},{"key":"12131_CR15","doi-asserted-by":"publisher","first-page":"108801","DOI":"10.1016\/j.pharmthera.2025.108801","volume":"267","author":"Z Wang","year":"2025","unstructured":"Wang Z, Liu J, Chen Y, Tang Y, Chen T, Zhou C, Wang S, Chang R, Chen Z, Yang W, Guo Z, Chen T (2025) From physiology to pathology: Emerging roles of GPER in cardiovascular disease. Pharmacol Ther 267:108801. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108801","journal-title":"Pharmacol Ther"},{"issue":"1","key":"12131_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1186\/s12967-025-07005-0","volume":"23","author":"L Liu","year":"2025","unstructured":"Liu L, Zhou Y, Liu J, Zhang X, He C, Zeng X, Dejenie R, Zeb U, Zeng Q, Liu L, Li J, Zeng X, Hu Q, Huang X, Xu X, Dong H, Zhong J, Huang Y, Lv Q, Liu B, Qiu YA, Yu T (2025) GPER in metabolic homeostasis and disease: molecular mechanisms, nutritional regulation, and therapeutic potential. J Transl Med 23(1):960. https:\/\/doi.org\/10.1186\/s12967-025-07005-0","journal-title":"J Transl Med"},{"issue":"2","key":"12131_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/ijms20020306","volume":"20","author":"LH Hsu","year":"2019","unstructured":"Hsu LH, Chu NM, Lin YF, Kao SH (2019) G-Protein Coupled Estrogen Receptor in Breast Cancer. Int J Mol Sci 20(2):306. https:\/\/doi.org\/10.3390\/ijms20020306","journal-title":"Int J Mol Sci"},{"issue":"10","key":"12131_CR18","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.3390\/cancers15102845","volume":"15","author":"S Sch\u00fcler-Toprak","year":"2023","unstructured":"Sch\u00fcler-Toprak S, Skrzypczak M, Gr\u00fcndker C, Ortmann O, Treeck O (2023) Role of estrogen receptor \u03b2, G-protein coupled estrogen receptor and estrogen-related receptors in endometrial and ovarian cancer. Cancers 15(10):2845. https:\/\/doi.org\/10.3390\/cancers15102845","journal-title":"Cancers"},{"issue":"1","key":"12131_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/andr.12131","volume":"4","author":"V Rago","year":"2016","unstructured":"Rago V, Romeo F, Giordano F, Ferraro A, Carpino A (2016) Identification of the G protein-coupled estrogen receptor (GPER) in human prostate: expression site of the estrogen receptor in the benign and neoplastic gland. Andrology 4(1):121\u2013127. https:\/\/doi.org\/10.1111\/andr.12131","journal-title":"Andrology"},{"key":"12131_CR20","doi-asserted-by":"publisher","first-page":"1333284","DOI":"10.3389\/fendo.2024.1333284","volume":"15","author":"C Rico-Fuentes","year":"2024","unstructured":"Rico-Fuentes C, L\u00f3pez-Pulido EI, P\u00e9rez-Guerrero EE, God\u00ednez-Rub\u00ed M, Villegas-Pineda JC, Villanueva-P\u00e9rez MA, Sierra-D\u00edaz E, Zepeda-Nu\u00f1o JS, Pereira-Su\u00e1rez AL, Ram\u00edrez-de-Arellano A (2024) Positive correlation between the nuclear expression of GPER and pGLI3 in prostate cancer tissues from patients with different Gleason scores. Front Endocrinol 15:1333284. https:\/\/doi.org\/10.3389\/fendo.2024.1333284","journal-title":"Front Endocrinol"},{"issue":"4","key":"12131_CR21","doi-asserted-by":"publisher","first-page":"167740","DOI":"10.1016\/j.bbadis.2025.167740","volume":"1871","author":"J Desouza","year":"2025","unstructured":"Desouza J, Khan R, Metkari S, Singh K, Narayanaswamy S, Fernandes G, Menon S, Sable N, Pal M, Chaudhari U, Patel V, Patwardhan S, Bakshi G, Sachdeva G (2025) G-protein coupled estrogen receptor 1 (GPER1): a potential target for chemoprevention of prostate cancer. Biochim Biophys Acta Mol Basis Dis 1871(4):167740. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167740","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"6","key":"12131_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1530\/ERC-14-0402","volume":"21","author":"HM Lam","year":"2014","unstructured":"Lam HM, Ouyang B, Chen J, Ying J, Wang J, Wu CL, Jia L, Medvedovic M, Vessella RL, Ho SM (2014) Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer. Endocr Relat Cancer 21(6):903\u2013914. https:\/\/doi.org\/10.1530\/ERC-14-0402","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"12131_CR23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/cdd.2010.20","volume":"17","author":"QK Chan","year":"2010","unstructured":"Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM (2010) Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1\/2, c-jun\/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 17(9):1511\u20131523. https:\/\/doi.org\/10.1038\/cdd.2010.20","journal-title":"Cell Death Differ"},{"issue":"1","key":"12131_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.yexcr.2016.11.022","volume":"350","author":"KM Lau","year":"2017","unstructured":"Lau KM, Ma FM, Xia JT, Chan QKY, Ng CF, To KF (2017) Activation of GPR30 stimulates GTP-binding of G\u03b1i1 protein to sustain activation of Erk1\/2 in inhibition of prostate cancer cell growth and modulates metastatic properties. Exp Cell Res 350(1):199\u2013209. https:\/\/doi.org\/10.1016\/j.yexcr.2016.11.022","journal-title":"Exp Cell Res"},{"issue":"10","key":"12131_CR25","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1210\/en.2008-1591","volume":"150","author":"II Park","year":"2009","unstructured":"Park II, Zhang Q, Liu V, Kozlowski JM, Zhang J, Lee C (2009) 17\u03b2-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. Endocrinology 150(10):4594\u20134605. https:\/\/doi.org\/10.1210\/en.2008-1591","journal-title":"Endocrinology"},{"issue":"8","key":"12131_CR26","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1210\/en.2016-1035","volume":"157","author":"B Jia","year":"2016","unstructured":"Jia B, Gao Y, Li M, Shi J, Peng Y, Du X, Klocker H, Sampson N, Shen Y, Liu M, Zhang J (2016) GPR30 promotes prostate stromal cell activation via suppression of ER\u03b1 expression and its downstream signaling pathway. Endocrinology 157(8):3023\u20133035. https:\/\/doi.org\/10.1210\/en.2016-1035","journal-title":"Endocrinology"},{"issue":"6","key":"12131_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41419-022-04979-3","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Sheng J, Hu S, Cui Y, Xiao J, Yu W, Peng J, Han W, He Q, Fan Y, Niu Y, Lin J, Tian Y, Chang C, Yeh S, Jin J (2022) Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis. Cell Death Dis 13(6):533. https:\/\/doi.org\/10.1038\/s41419-022-04979-3","journal-title":"Cell Death Dis"},{"issue":"3","key":"12131_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbrc.2017.04.047","volume":"487","author":"DL Yang","year":"2017","unstructured":"Yang DL et al (2017) Role of GPR30 in estrogen-induced prostate epithelial apoptosis and benign prostatic hyperplasia. Biochem Biophys Res Commun 487(3):517\u2013524. https:\/\/doi.org\/10.1016\/j.bbrc.2017.04.047","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"12131_CR29","doi-asserted-by":"publisher","first-page":"109125","DOI":"10.1016\/j.isci.2024.109125","volume":"27","author":"Z Liu","year":"2024","unstructured":"Liu Z, Li S, Chen S, Sheng J, Li Z, Lv T, Yu W, Fan Y, Wang J, Liu W, Hu S, Jin J (2024) YAP-mediated GPER signaling impedes proliferation and survival of prostate epithelium in benign prostatic hyperplasia. iScience 27(3):109125. https:\/\/doi.org\/10.1016\/j.isci.2024.109125","journal-title":"iScience"},{"issue":"1\u20132","key":"12131_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jsbmb.2009.09.001","volume":"118","author":"M Giess","year":"2010","unstructured":"Giess M, Lattrich C, Springwald A, Goerse R, Ortmann O, Treeck O (2010) GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients. J Steroid Biochem Mol Biol 118(1\u20132):7\u201312. https:\/\/doi.org\/10.1016\/j.jsbmb.2009.09.001","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"12131_CR31","doi-asserted-by":"publisher","first-page":"e06428","DOI":"10.1016\/j.heliyon.2021.e06428","volume":"7","author":"ZS Ulhaq","year":"2021","unstructured":"Ulhaq ZS, Soraya GV, Milliana A, Tse WKF (2021) Association between GPER gene polymorphisms and GPER expression levels with cancer predisposition and progression. Heliyon 7(3):e06428. https:\/\/doi.org\/10.1016\/j.heliyon.2021.e06428","journal-title":"Heliyon"},{"issue":"29","key":"12131_CR32","doi-asserted-by":"publisher","first-page":"46728","DOI":"10.18632\/oncotarget.18156","volume":"8","author":"M Pupo","year":"2017","unstructured":"Pupo M, Bodmer A, Berto M, Maggiolini M, Dietrich PY, Picard D (2017) A genetic polymorphism repurposes the G-protein coupled and membrane-associated estrogen receptor GPER to a transcription factor-like molecule promoting paracrine signaling between stroma and breast carcinoma cells. Oncotarget 8(29):46728\u201346744. https:\/\/doi.org\/10.18632\/oncotarget.18156","journal-title":"Oncotarget"},{"issue":"S1","key":"12131_CR33","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1038\/modpathol.2017.133","volume":"31","author":"JI Epstein","year":"2018","unstructured":"Epstein JI (2018) Prostate cancer grading: a decade after the 2005 modified system. Mod Pathol 31(S1):S47\u2013S63. https:\/\/doi.org\/10.1038\/modpathol.2017.133","journal-title":"Mod Pathol"},{"issue":"4","key":"12131_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CU9.0000000000000145","volume":"16","author":"A Tidd-Johnson","year":"2022","unstructured":"Tidd-Johnson A, Sebastian SA, Co EL, Afaq M, Kochhar H, Sheikh M, Mago A, Poudel S, Fernandez JA, Rodriguez ID, Razdan S (2022) Prostate cancer screening: continued controversies and novel biomarker advancements. Curr Urol 16(4):197\u2013206. https:\/\/doi.org\/10.1097\/CU9.0000000000000145","journal-title":"Curr Urol"},{"key":"12131_CR35","doi-asserted-by":"publisher","first-page":"111643","DOI":"10.1016\/j.mehy.2025.111643","volume":"199","author":"R Venkatesan","year":"2025","unstructured":"Venkatesan R, Muthu S, Jayaram S, Selvaraj D (2025) Estrogen signaling in prostate cancer: novel ways to reactivate ER-\u03b2 in castration-resistant prostate cancer. Med Hypotheses 199:111643. https:\/\/doi.org\/10.1016\/j.mehy.2025.111643","journal-title":"Med Hypotheses"},{"issue":"1","key":"12131_CR36","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3390\/ijms15011574","volume":"15","author":"N Chevalier","year":"2014","unstructured":"Chevalier N, Paul-Bellon R, Camparo P, Michiels JF, Chevallier D, F\u00e9nichel P (2014) Genetic variants of GPER\/GPR30, a novel estrogen-related G protein receptor, are associated with human seminoma. Int J Mol Sci 15(1):1574\u20131589. https:\/\/doi.org\/10.3390\/ijms15011574","journal-title":"Int J Mol Sci"},{"issue":"6","key":"12131_CR37","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/09513590.2018.1540572","volume":"35","author":"DG Hong","year":"2019","unstructured":"Hong DG, Park JY, Chong GO, Lee YH, Lee HJ, Shinn JU, Lee YS, Seong WJ (2019) Transmembrane G protein-coupled receptor 30 gene polymorphisms and uterine adenomyosis in Korean women. Gynecol Endocrinol 35(6):498\u2013501. https:\/\/doi.org\/10.1080\/09513590.2018.1540572","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"12131_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000369013","volume":"83","author":"HA Korkmaz","year":"2015","unstructured":"Korkmaz HA, Edg\u00fcnl\u00fc T, Eren E, Demir K, \u00c7akir ED, \u00c7elik SK, \u00d6zkan B (2015) GPR30 gene polymorphisms are associated with gynecomastia risk in adolescents. Horm Res Paediatr 83(3):177\u2013182. https:\/\/doi.org\/10.1159\/000369013","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"12131_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.17305\/bjbms.2016.683","volume":"16","author":"B Kasap","year":"2016","unstructured":"Kasap B, \u00d6zt\u00fcrk Turhan N, Edg\u00fcnl\u00fc T, Duran M, Akbaba E, \u00d6ner G (2016) G-protein-coupled estrogen receptor-30 gene polymorphisms are associated with uterine leiomyoma risk. Bosn J Basic Med Sci 16(1):39\u201345. https:\/\/doi.org\/10.17305\/bjbms.2016.683","journal-title":"Bosn J Basic Med Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12131-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12131-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12131-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:16:23Z","timestamp":1781784983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12131-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12131"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12131-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"946"}}